ACCC Announces the Release of New Resources for the Integration of Oral Oncolytics into CLL Practice

Rockville, MD – The treatment of patients with Chronic Lymphocytic Leukemia (CLL) has shifted substantially in the past five years from intravenous treatments (IV) to oral oncolytics. With this transition towards oral therapies, cancer care teams face different challenges such as medication adherence, polypharmacy, financial toxicity, and interruptions in continuity of care due to oral prescriptions and outside pharmacies. As the use of oral oncolytics increases, cancer programs must prepare for the successful implementation of oral therapy programs.

Effective integration of oral oncolytics into community practice depends on multidisciplinary team collaboration, assessment of patient specific CLL treatment goals, accurate and efficient medication dispensing, patient education, medication adherence, and thorough data capture.

The Association of Community Cancer Centers (ACCC) today announced the release of new resources aimed at supporting cancer care teams in the effective integration of oral oncolytics into the CLL cancer care continuum.

Resources include:

• Effective Practice Guide: Steps to Success: Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia (CLL) Practice. The Guide features an Oral Oncolytic Clinical Workflow for Treatment of Patients with Chronic Lymphocytic Leukemia.
• Care Coordination: Multidisciplinary Approach in Integrating Oral Oncolytics into CLL Practice (Webinar)
• Nurses’ Role in Oral Oncolytics for CLL – [VIDEO PODCAST] Ep 28
• Successful Integration of Oral Oncolytics — [PODCAST] EP 96
• Blog: Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia Practice

Resources are available on ACCC’s website, found here.

“Outcomes for patients with CLL have drastically improved with advances in oral therapies. A collaborative group of experts within ACCC evaluated nationwide, best practices for optimizing care delivery with oral therapies for CLL. Checkout these resources!”

—  Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, Director of Pharmacy at Minnesota Oncology, and Assistant Professor of Pharmacy at the Mayo Clinic College

This project was made possible by support from AbbVie.